OBJECTIVE: To determine the effect of introduction of highly active antiretroviral therapy (HAART) on survival following AIDS dementia complex (ADC). METHODS: Australian AIDS notification data in the period 1993-2000 were examined. In order to examine the impact of HAART, two periods of AIDS diagnoses were chosen: pre-HAART (1993-1995) and HAART (1996-2000). Median survival was based on Kaplan-Meier estimates, with examination of factors influencing survival in a Cox proportional hazards model. RESULTS: In the period 1993-2000 in Australia, 5017 initial AIDS illnesses were diagnosed among 4351 AIDS patients. The proportion of AIDS cases with ADC increased from 5.2% in 1993-1995 to 6.8% in 1996-2000 (P = 0.029). Median survival following AIDS increased from 19.6 months for those diagnosed with AIDS in 1993-1995 to 39.6 months for those diagnosed in 1996-2000 (P < 0.0005). Median survival following ADC increased to a greater extent than that for all other AIDS illnesses, from 11.9 months in 1993-1995 to 48.2 in 1996-2000 (P < 0.0005). Most striking was the increase in survival among those with ADC and a CD4 cell count < 100 x 10(6) cells/l at diagnosis; 5.1 months in 1993-1995 to 38.5 months in 1996-2000 (P < 0.0005). CONCLUSION: Although there has been a proportional increase in ADC at AIDS diagnosis, survival following ADC has improved markedly in the era of HAART.
OBJECTIVE: To determine the effect of introduction of highly active antiretroviral therapy (HAART) on survival following AIDS dementia complex (ADC). METHODS: Australian AIDS notification data in the period 1993-2000 were examined. In order to examine the impact of HAART, two periods of AIDS diagnoses were chosen: pre-HAART (1993-1995) and HAART (1996-2000). Median survival was based on Kaplan-Meier estimates, with examination of factors influencing survival in a Cox proportional hazards model. RESULTS: In the period 1993-2000 in Australia, 5017 initial AIDS illnesses were diagnosed among 4351 AIDSpatients. The proportion of AIDS cases with ADC increased from 5.2% in 1993-1995 to 6.8% in 1996-2000 (P = 0.029). Median survival following AIDS increased from 19.6 months for those diagnosed with AIDS in 1993-1995 to 39.6 months for those diagnosed in 1996-2000 (P < 0.0005). Median survival following ADC increased to a greater extent than that for all other AIDS illnesses, from 11.9 months in 1993-1995 to 48.2 in 1996-2000 (P < 0.0005). Most striking was the increase in survival among those with ADC and a CD4 cell count < 100 x 10(6) cells/l at diagnosis; 5.1 months in 1993-1995 to 38.5 months in 1996-2000 (P < 0.0005). CONCLUSION: Although there has been a proportional increase in ADC at AIDS diagnosis, survival following ADC has improved markedly in the era of HAART.
Authors: Andrew J Levine; Susan Service; Eric N Miller; Sandra M Reynolds; Elyse J Singer; Paul Shapshak; Eileen M Martin; Ned Sacktor; James T Becker; Lisa P Jacobson; Paul Thompson; Nelson Freimer Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2012-05-24 Impact factor: 3.568
Authors: Mahfuz B Khan; Michelle J Lang; Ming-Bo Huang; Andrea Raymond; Vincent C Bond; Bruce Shiramizu; Michael D Powell Journal: J Neurovirol Date: 2015-09-25 Impact factor: 2.643
Authors: A Antinori; G Arendt; J T Becker; B J Brew; D A Byrd; M Cherner; D B Clifford; P Cinque; L G Epstein; K Goodkin; M Gisslen; I Grant; R K Heaton; J Joseph; K Marder; C M Marra; J C McArthur; M Nunn; R W Price; L Pulliam; K R Robertson; N Sacktor; V Valcour; V E Wojna Journal: Neurology Date: 2007-10-03 Impact factor: 9.910
Authors: Andrew J Levine; Steve Horvath; Eric N Miller; Elyse J Singer; Paul Shapshak; Gayle C Baldwin; Otoniel Martínez-Maza; Mallory D Witt; Peter Langfelder Journal: J Neuroimmunol Date: 2013-09-26 Impact factor: 3.478
Authors: Karl Goodkin; Francisco Fernandez; Marshall Forstein; Eric N Miller; James T Becker; Antoine Douaihy; Luis Cubano; Flavia H Santos; Nelson Silva Filho; Jorge Zirulnik; Dinesh Singh Journal: Neuropsychiatry (London) Date: 2011-10-01